Stock NVAX NOVAVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
15.04 USD -1.38% Intraday chart for Novavax, Inc. -2.97% +213.33%
May. 24 Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE
May. 23 Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating
MT
Novavax Stockholder Shah Capital Withdraws Campaign Against Reelection of Directors
MT
Shah Capital withdraws campaign against three Novavax directors
RE
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance
MT
Novavax Stock Price More Than Doubles After COVID-19 Vaccine Licensing Deal With Sanofi
MT
HEDGE FUND SHAH CAPITAL SAYS NOVAVAX-SANOFI DEAL IS "A STEP IN T…
RE
HEDGE FUND SHAH CAPITAL - NOVAVAX-SANOFI DEAL CONCURS WITH SHAH…
RE
Novavax's Shareholder Shah Capital Urges Vote Against Re-Election of Directors
MT
Novavax's top shareholder Shah Capital ramps up efforts for board shakeup
RE
Shah Capital urges Novavax shareholders to vote against three directors
RE
Novavax investor Shah Capital to vote against three directors
RE
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board
MT
Hedge fund Shah Capital urges Novavax board shake-up, FT says
RE
Hedge fund Shah Capital urges board shake-up at Novavax over struggling Covid vaccine, FT reports
RE
HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating
MT
B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating
MT
WHO sees 'incredibly low' COVID, flu vaccination rates as cases surge
RE
Novavax: green light for updated Covid vaccine in Sweden
CF
Job losses delight investors
Our Logo
B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. News Novavax, Inc.
  5. Analyst Reco.